On January 14, at the press conference of SINOVAC's winning bid for the Chilean project, Meng Weining, Vice President and Head of International Business of Sinovac, introduced that on January 10, the trivalent influenza vaccine Anerlife® produced by Beijing Sinovac Biological Products Co., Ltd. under SINOVAC Sinovac exclusively won the bid for the Chilean government's 2025 annual influenza vaccine global tender. The first batch of vaccines will be sent to Chile on January 15.

Meng Weining said that this winning bid means that the influenza vaccines that the Chilean government will provide free of charge to the people of the country in 2025 will all be provided by Sinovac. This is an important breakthrough for Sinovac in the influenza vaccine market in the southern hemisphere, breaking the monopoly of multinational companies in the Chilean market for many years.

According to reports, since 2020, Sinovac has supplied a total of 22 million doses of multi-category vaccines to Chile, including new crown vaccines, influenza vaccines, hepatitis A vaccines, etc.

At present, Sinovac is accelerating its international layout and has carried out diversified cooperation with many partners in Latin America, Asia and Africa. Meng Weining also introduced that the Chilean government has determined the strategic goal of developing vaccine research and development and industrialization in the country, and will strongly support Sinovac's local project cooperation and promote the project. While supplying vaccines, Sinovac is also preparing to start investing in the construction of a vaccine production base in Chile to ensure the vaccine needs of Chile and Latin American countries.

https://finance.eastmoney.com/a/202501143296916614.html